|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 50 F Street N.W., Suite 440 |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105877-52420
|
||||||||
|
6. House ID# 449740026
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Ryan Kelly |
Date | 1/21/2025 9:53:27 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Congress is asked to contact VA leadership to urge a halt to this risky VA initiative and to support the inclusion
of provisions from H.R. 3347/S.2070, the Protect Lifesaving Anesthesia Care for Veterans Act, in any Veterans'
legislation considered this year.
Congress should use its authority to curtail the harmful behavior of insurance companies including:
Holding United Health Group (UHG) and Change Healthcare (CHC) accountable for fully repairing the harm to physicians and for ensuring future protections from unexpected delays in claims processing and payment.
Scrutinizing insurance companies that divert premium dollars away from patient care for the sake of corporate profits.
Ensuring the enforcement of the mechanisms of the No Surprises Act requiring timely insurers' payments to prevailing parties in the IDR process.
Ensuring the enforcement of the mechanisms of the No Surprises Act requiring timely insurers' payments to prevailing parties in the IDR process.
Passing legislation to address insurers' prior authorization abuse.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryan |
Kelly |
|
President and CEO |
|
Emily |
Tranter |
|
Lead Lobbyist |
|
Greg |
Rubio |
|
Federal and Regulatory Affairs Professional |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Asking Congress to cosponsor H.R. 2474, the Strengthening Medicare for Patients and Providers Act, which would align Medicare physician payments with other sectors of Medicare by adding a mandatory annual inflation update.
To also cosponsor H.R. 6371, the Provider Reimbursement Stability Act, which would increase the budget-neutrality threshold, set limits on conversion factor variance, and allow CMS to enhance accountability and stability within the physician payment system.
Support H.R. 5625, the Fentanyl Awareness for Children and Teens in Schools (FACTS) Act, which would help
to address the opioid crisis by making naloxone available in school settings.
Support H.R. 5420 / S. 2948, the Workplace Overdose Reversal Kits (WORK) to Save Lives Act which would require opioid overdose reversal medications to be in federal buildings and create non-mandatory guidance for private employers on how to obtain these medications; both important measures to reduce opioid overdose fatalities.
Support H.R. 6161, the Supporting Access to Vital and Affordable Care for Everyone (SAVE) Act, which would make access to over-the-counter naloxone more affordable by ensuring it qualifies as a deductible medical expense.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryan |
Kelly |
|
President and CEO |
|
Emily |
Tranter |
|
Lead Lobbyist |
|
Greg |
Rubio |
|
Federal and Regulatory Affairs Professional |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |